Korsana
Waltham, US · 7 known investors
Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's. Its approach uses antibody engineering to enable therapies with meaningful central nervous system exposure delivered subcutaneously.
BiotechDeep TechHealthtech
Founders & leadership
MV
Mark VignolaChief Financial Officer
JV
Jonathan ViolinPresident
Investors · 7
Sanofi VenturesCambridge · $5M
TCG CrossoverPalo Alto
VenrockreportedPalo Alto · $500K – $10M
Wellington ManagementreportedBoston · $5M – $50M
Also in the syndicate · 3
FairmountJ.P. Morgan Life Sciences Private CapitalTCGX
Funding
SEC filings, press & company announcements$175M disclosed across 1 of 2 rounds · 2026
- Undisclosed amountSeries AFeb 2026
J.P. Morgan Life Sciences Private Capital, Sanofi Ventures, Wellington Management
Source ↗ - $175MraisedFeb 2026 · 4 sources
Fairmount, TCGX, Venrock, Wellington Management
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
2 people who came through Korsana went on to found or lead other companies.
In the news
Frequently asked questions
- What does Korsana do?
- Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's. Its approach uses antibody engineering to enable therapies with meaningful central nervous system exposure delivered subcutaneously.
- Who are Korsana's investors?
- Korsana's investors include Sanofi Ventures, TCG Crossover, Venrock, Wellington Management.
- How much funding has Korsana raised?
- Korsana has disclosed $175M raised across 1 of its 2 known rounds.
- Where is Korsana headquartered?
- Korsana is headquartered in Waltham, US.